Search

Your search keyword '"Deegen P"' showing total 3 results
Start Over Author "Deegen P" Journal blood
3 results on '"Deegen P"'

1. Generation of Half-Life Extended Anti-BCMA Bite® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of Multiple Myeloma (MM)

Author

Goyos, Ana, Li, Chi-Ming, Deegen, Petra, Bogner, Pamela, Thomas, Oliver, Matthias, Klinger, Wahl, Joachim, Goldstein, Rebecca, Coxon, Angela, Balazs, Mercedesz, and Chapman-Arvedson, Tara

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by accumulation of abnormal plasma cells in the bone marrow. Although several treatment options are available, patients frequently develop relapsed/refractory disease leading to significant morbidity and mortality. More effective induction and elimination of residual disease are required for curative treatments. One potential strategy for improving patient outcomes is the use of T cell engaging agents such as BiTE® antibody constructs and CAR-T cells.

Published
2017
Full Text
View/download PDF

2. BI 836909, a Novel Bispecific T Cell Engager for the Treatment of Multiple Myeloma Induces Highly Specific and Efficacious Lysis of Multiple Myeloma Cells in Vitro and Shows Anti-Tumor Activity in Vivo

Author

Hipp, Susanne, Deegen, Petra, Wahl, Joachim, Blanset, Diann, Thomas, Oliver, Rattel, Benno, Adam, Paul, and Friedrich, Matthias

Abstract

Hipp: Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, 1121 Vienna, Austria: Employment. Deegen:Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany: Employment. Wahl:Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany: Employment. Blanset:Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA: Employment. Thomas:Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany: Employment. Rattel:Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich, Germany: Employment. Adam:Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, 1121 Vienna, Austria: Employment. Friedrich:Amgen Research (Munich) GmbH: Employment.

Published
2015
Full Text
View/download PDF

3. BI 836909, a Novel Bispecific T Cell Engager for the Treatment of Multiple Myeloma Induces Highly Specific and Efficacious Lysis of Multiple Myeloma Cells in Vitroand Shows Anti-Tumor Activity in Vivo

Author

Hipp, Susanne, Deegen, Petra, Wahl, Joachim, Blanset, Diann, Thomas, Oliver, Rattel, Benno, Adam, Paul, and Friedrich, Matthias

Abstract

BI 836909 is a Bispecific T cell Engager (BiTE®), designed to redirect the body's endogenous T cells towards cells expressing B cell maturation antigen (BCMA) on the cell surface.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results